David Allison, PhD


David Allison, Ph.D. joined 5AM Ventures as a Principal in 2016.  He was previously a Principal at Versant Ventures, where he focused on biotechnology and other healthcare investments, and was involved with companies such as Aprea, BioTie Therapies (acquired by Acorda), Crinetics, Holaira and NeuWave Medical (acquired by Johnson and Johnson).  Prior to Versant, Dr. Allison was a Principal at Split Rock Ventures where he was involved with companies such as Ardian (acquired by Medtronic), Histogenics (Nasdaq: HSGX), RF Surgical (acquired by Medtronic), Transcend (acquired by Alcon) and Twelve (acquired by Medtronic).  Prior to Split Rock Ventures he was a Sr. Associate at PTV Sciences.  David also spent time with SurModics in its diagnostics and drug discovery business unit and as a NSF Research Fellow at The Cleveland Clinic Foundation’s Heart Valve Laboratory.  Dr. Allison received a Ph.D. in Bioengineering from Rice University with a focus in Cell Biology and Extracellular Matrix in Cardiovascular Disease. He received a B.S. in Biomedical Engineering from The University of Iowa. Dr. Allison is based in the San Francisco, CA office.